A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Borner, M M; Bernhard, Jacqueline Simone; Dietrich, D.; Popescu, R; Wernli, Marie; Saletti, P; Rauch, D; Herrmann, R; Koeberle, D; Honegger, H; Brauchli, Patrik Olivier; Lanz, D; Roth, Arnaud

doi:10.1093/annonc/mdi047

Scientific article

English

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

ContributorsBorner, M M; Bernhard, Jacqueline Simone; Dietrich, D.; Popescu, R; Wernli, Marie; Saletti, P; Rauch, D; Herrmann, R; Koeberle, D; Honegger, H; Brauchli, Patrik Olivier; Lanz, D; Roth, Arnaud

Published inAnnals of oncology, vol. 16, no. 2, p. 282-288

Publication date2005

Abstract

To determine the efficacy, impact on quality-of-life (QoL) and tolerability of two different irinotecan administration schedules in combination with capecitabine as first-line treatment of metastatic colorectal cancer.

Keywords

Adult
Aged
Antimetabolites, Antineoplastic/administration & dosage/adverse effects/therapeutic use
Antineoplastic Agents, Phytogenic/administration & dosage/adverse effects/therapeutic use
Camptothecin/administration & dosage/adverse effects/analogs & derivatives/therapeutic use
Colorectal Neoplasms/drug therapy/pathology
Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives/therapeutic use
Drug Administration Schedule
Female
Fluorouracil/analogs & derivatives
Humans
Infusions, Intravenous
Male
Middle Aged
Quality of Life
Treatment Outcome

Affiliation entities

Research groups

Groupe Roth Arnaud (oncologie) (285)

Citation (ISO format)

BORNER, M M et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. In: Annals of oncology, 2005, vol. 16, n° 2, p. 282–288. doi: 10.1093/annonc/mdi047

Article (Published version)

Identifiers

PID : unige:39622
DOI : 10.1093/annonc/mdi047
PMID : 15668285

Journal ISSN0923-7534

641views

313downloads

Creation20/08/2014 12:21:00

First validation20/08/2014 12:21:00

Update14/03/2023 21:32:24

Status update14/03/2023 21:32:24

Last indexation30/10/2024 19:47:26

Archive ouverte UNIGE

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

To determine the efficacy, impact on quality-of-life (QoL) and tolerability of two different irinotecan administration schedules in combination with capecitabine as first-line treatment of metastatic colorectal cancer.

Technical informations